DMD and Duchenne muscular dystrophy: The DMD deletion described has the potential to be clinically relevant in 60% of DMD patient mutations; thus, the authors highlighted the significant therapy potential of a single pair of guide RNAs (gRNAs) to treat a great number of DMD patients.